Table 2.
Association between overanticoagulation (INR ≥6) under acenocoumarol maintenance treatment and SSRIs
| Number of patients with drug use within total cohort*(n = 2755) | Cases with use of a specific drug with at least one INR ≥6.0 | Andersen-Gill analysis* | ||
|---|---|---|---|---|
| SSRI | HR†(95% CI) | HR‡(95% CI) | ||
| Fluoxetine | 18 | 1 | 0.50 (0.07, 3.55) | 0.48 (0.07, 3.40) |
| Citalopram | 32 | 3 | 0.62 (0.20, 1.94) | 0.63 (0.20, 1.95) |
| Paroxetine | 97 | 18 | 1.15 (0.81, 1.65) | 0.99 (0.68, 1.44) |
| Sertraline | 23 | 2 | 1.07 (0.34, 3.34) | 1.02 (0.33, 3.18) |
| Fluvoxamine | 36 | 8 | 2.46 (1.39, 4.34) | 2.63 (1.49, 4.66) |
| Escitalopram | 2 | 0 | P = 0.95 | P = 0.95 |
| Venlafaxine | 14 | 6 | 2.37 (1.37, 4.10) | 2.19 (1.21, 3.99) |
| Sub-analysis | ||||
| Nortriptyline | 12 | 2 | 0.60 (0.25, 1.44) | 0.55 (0.21, 1.47) |
| Mirtazapine | 45 | 8 | 1.01 (0.54, 1.88) | 1.09 (0.58, 2.04) |
Statistically significant values are printed in bold.
In this time-dependent analysis, exposure in case patient and in the rest of the cohort is assessed at the time of the outcome in each case patient (index date). As control patients can be used multiple times, the number of assessments in the reference group is much larger than the number of individuals. Hence, crude RRs cannot be calculated from the data in this table.
Adjusted for age, gender, BMI and target INR; if none of the cases was exposed, P values are given instead of HRs.
Adjusted for age, gender, BMI, target INR and use of non-steroidal anti-inflammatory drugs (ATC-group M01A) or proton pump inhibitors (A02 BC) if none of the cases was exposed, P values are given instead of HRs.